Uncategorized
Teprotumumab more effective than placebo in treating active ophthalmopathy
Teprotumumab may be an effective therapeutic strategy to inhibit the insulin-like growth factor 1 receptor and reduce proptosis in patients with thyroid-associated ophthalmopathy, according to a study. The multicenter, double-masked, randomized, placebo-controlled trial included 87 patients with active moderate to severe ophthalmopathy, randomly assigned to treatment with placebo or teprotumumab (River Vision Development) administered intravenously once every 3 weeks for eight total infusions; 45 patients were in the placebo group and 42 in the teprotumumab group. The intervention lasted for 24 weeks.